Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit
Søren Lund Kristensen(Novo Nordisk (Denmark)), Jens Jakob Thune(Amager Hospital), Lars Videbæk(Odense University Hospital), Steen Pehrson(Copenhagen University Hospital), Henrik Wiggers(Aarhus University), Lars Køber(University of Copenhagen), James Signorovitch(Analysis Group (United States)), Anna Margrethe Thøgersen(Aalborg University Hospital), Axel Brandes(Odense University Hospital), Niels Eske Bruun(Diabetes Australia), Jens Haarbo(University of Copenhagen), Dan Eik Høfsten(University of Copenhagen), Jesper Hastrup Svendsen(University of Copenhagen), Hans Eiskjær(Aarhus University Hospital), Wayne C. Levy(Pfizer (United States)), Christian Torp‐Pedersen(University of Copenhagen), Jens Cosedis Nielsen(Aarhus University), Ramin Shadman(Los Angeles Medical Center), Christian Hassager(University of Copenhagen)
Cited by 43
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
|Heart Rhythm|2017|2.7k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k